| Name | No. | For Patients with | Purpose |
|---|---|---|---|
| NATALEE | 18-41 (CLEE011O12301C) | Early Breast Cancer |
The purpose of this study is to evaluate efficacy and safety of ribociclib with endocrine therapy as adjuvant treatment in patients with HR+/HER2- Early Breast Cancer. |
DSSG Group: Breast
KEYNOTE-756
| Name | No. | For Patients with | Purpose |
|---|---|---|---|
| KEYNOTE-756 | 18-05 (MK-3475-756) | Newly Diagnosed Breast Cancer |
The purpose of this study is to assess the efficacy and safety of pembrolizumab in combination with pre-surgery chemotherapy and post-surgery endocrine therapy in the treatment of adults who have high-risk early-stage ER+/HER2- breast cancer. |
ALEXANDRA/IMpassion030
| Name | No. | For Patients with | Purpose |
|---|---|---|---|
| ALEXANDRA/IMpassion030 | 17-15 (WO39391 / BIG 16-05) | Early stage breast cancer |
This study will evaluate the efficacy, safety, and pharmacokinetics of adjuvant atezolizumab. |
Proteomics / Molecular Breast
| Name | No. | For Patients with | Purpose |
|---|---|---|---|
| Proteomics / Molecular Breast | 09-07 | Breast cancer |
The purpose of this trial is to examine the function of different genes and proteins, previously identified to be of interest, and identify new ones, as well as the means by which they interact and differ between cancer cells. |